In addition, OCT LAR (30 mg intramuscular (im) every 28 days) significantly ameliorates the time to tumour progression (TTP) when compared to placebo in either functioning (hormone secreting) or non-functioning (non-secreting) metastatic well-differentiated midgut NETs [4,5], and registered in the PROMID trial a stabilization rate of 60%. Here, PLXNA2 is linked to neoplasm.